Translating the science of aging into therapeutic interventions

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 3, 2016, Pages

  Kirkland, James L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

AGING; ARTICLE; BIOLOGY; CLINICAL TRIAL (TOPIC); COMORBIDITY; COPING BEHAVIOR; FATALITY; GERIATRIC DISORDER; GERIATRICS; HEALTH STATUS; HUMAN; LIFESPAN; MEDICAL RESEARCH; NONHUMAN; ANIMAL; PHYSIOLOGY; PRECLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGING; ANIMALS; BIOMARKERS; BIOMEDICAL RESEARCH; DRUG EVALUATION, PRECLINICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84959528564     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a025908     Document Type: Article

References (120)

1. Alliance for Aging Research. 2012. Chronic disease and medical innovation in an aging nation. Silver Book,Washington, DC.
2. Anderson RM, Weindruch R. 2012. The caloric restriction paradigm: Implications for healthy human aging. Am J Hum Biol 24: 101-106.
3. Anfossi G, Russo I, Bonomo K, Trovati M. 2010. The cardiovascular effects of metformin: Further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol 8: 327-337.
4. Anisimov VN, Bartke A. 2013. The key role of growth hormone- insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol 87: 201-223.
5. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV, Kovalenko IG, Poroshina TE, et al. 2008.Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 7: 2769-2773.
6. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS, Romanyukha AA. 2010.Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 9: 188-197.
7. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Kovalenko IG, et al. 2011. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Milano) 3: 148-157.
8. Baker DJ, Perez-Terzic C, Jin F, Pitel KS, Niederlander NJ, Jeganathan K, Yamada S, Reyes S, Rowe L, Hiddinga HJ, et al. 2008. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat Cell Biol 10: 825-836.
9. Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, Kirkland JL, van Deursen JM. 2011. Clearance of p16Ink4a-positive senescent cells delays ageing- associated disorders. Nature 479: 232-236.
10. Bandeen-Roche K, Xue QL, Ferrucci L, Walston J, Guralnik JM, Chaves P, Zeger SL, Fried LP. 2006. Phenotype of frailty: Characterization in the women’s health and aging studies. J Gerontol A Biol Sci Med Sci 61: 262-266.
11. Bandeen-Roche K, Walston JD, Huang Y, Semba RD, Ferrucci L. 2009. Measuring systemic inflammatory regulation in older adults: Evidence and utility. Rejuvenation Res 12: 403-410.
12. Bannister CA, Holden SE, Jenkins-Jones S, Morgan CL, Halcox JP, Schernthaner G, Mukherjee J, Currie CJ. 2014. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 16: 1165-1173.
13. Bartke A. 2011. Single-gene mutations and healthy ageing in mammals. Philos Trans R Soc Lond B Biol Sci 366: 28-34.
14. Basso N, Paglia N, Stella I, de Cavanagh EM, Ferder L, del Rosario Lores Arnaiz M, Inserra F. 2005. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept 128: 247-252.
15. Basso N, Cini R, Pietrelli A, Ferder L, Terragno NA, Inserra F. 2007. Protective effect of long-term angiotensin II inhibition. Am J Physiol Heart Circ Physiol 293: H1351-H1358.
16. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. 2012. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov 11: 443-461.
17. Benson EK, Lee SW, Aaronson SA. 2010. Role of progerininduced telomere dysfunction in HGPS premature cellular senescence. J Cell Sci 123: 2605-2612.
18. Brown DW, Giles WH, Croft JB. 2001. White blood cell count: An independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 54: 316-322.
19. Bruunsgaard H, Pedersen BK. 2003. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 23: 15-39.
20. Bruunsgaard H, Andersen-Ranberg K, Hjelmborg JB, Pedersen BK, Jeune B. 2003. Elevated levels of tumor necrosis factor a and mortality in centenarians. Am J Med 115: 278-283.
21. Calhoun C, Shivshankar P, Saker M, Sloane LB, Livi CB, Sharp ZD, Orihuela CJ, Adnot S, White ES, Richardson A, et al. 2015. Senescent cells contribute to the physiological remodeling of aged lungs. J Gerontol A Biol Sci Med Sci doi: 10.1093/gerona/glu241.
22. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Tracy RP, Rubin SM, Harris TB, Pahor M. 2003. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol 92: 522-528.
23. Chen Q, Liu K, Robinson AR, Clauson CL, Blair HC, Robbins PD, Niedernhofer LJ, Ouyang H. 2013.DNAdamage drives accelerated bone aging via an NF-kB-dependent mechanism. J Bone Miner Res 28: 1214-1228.
24. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. 2002. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 359: 2072-2077.
25. Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D’Avanzo C, Chen H, Hooli B, Asselin C, Muffat J, et al. 2014. A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature 515: 274-278.
26. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. 2005. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 433: 760-764.
27. Crandall J, Schade D, Ma Y, Fujimoto WY, Barrett-Connor E, Fowler S, Dagogo-Jack S, Andres R. 2006. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 61: 1075-1081.
28. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. 2011. Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. J Alzheimers Dis 26: 699-708.
29. De Felice FG, Ferreira ST. 2014. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63: 2262-2272.
30. Dykens JA, Moos WH, Howell N. 2005. Development of 17a-estradiol as a neuroprotective therapeutic agent: Rationale and results from a phase I clinical study. Ann NYAcad Sci 1052: 116-135.
31. Eren M, Boe AE, Murphy SB, Place AT, Nagpal V, Morales- Nebreda L, Urich D, Quaggin SE, Budinger GR, Mutlu GM, et al. 2014. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. ProcNatl Acad Sci 111: 7090-7095.
32. Ferder L, Inserra F, Romano L, Ercole L, Pszenny V. 1993. Effects of angiotensin-converting enzyme inhibition on mitochondrial number in the aging mouse. Am J Physiol 265: C15-C18.
33. Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, Penninx B, Pahor M, Wallace R, Havlik RJ. 1999. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 47: 639-646.
34. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, et al. 2001. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56: M146-M156
35. Fried LP, Xue QL, Cappola AR, Ferrucci L, Chaves P, Varadhan R, Guralnik JM, Leng SX, Semba RD, Walston JD, et al. 2009. Nonlinear multisystem physiological dysregulation associated with frailty in older women: Implications for etiology and treatment. J Gerontol A Biol Sci Med Sci 64: 1049-1057.
36. Fry PS. 2000.Whose quality of life is it anyway?Why not ask seniors to tell us about it? Int J Aging Hum Dev 50: 361-383.
37. Fry PS, Debats DL. 2006. Sources of life strengths as predictors of late-life mortality and survivorship. Int J Aging Hum Dev 62: 303-334.
38. Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE. 2013. Salicylate (salsalate) in patients with type 2 diabetes: A randomized trial. Ann Intern Med 159: 1-12.
39. Goldman DP, Cutler D, Rowe JW, Michaud PC, Sullivan J, Peneva D, Olshansky SJ. 2013. Substantial health and economic returns from delayed aging may warrant a new focus for medical research. Health Aff (Millwood) 32: 1698-1705.
40. Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nadhazi Z, Petrella R, Sedefdjian A, Sevenier F, Shlyakhto EV, Pathak A. 2008. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: Primary results of the Observational Study on Cognitive Function and Systolic Blood Pressure Reduction Open-Label Study. J Hypertens 26: 1642-1650.
41. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R. 1999. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106: 506-512.
42. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, et al. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460: 392-395.
43. Harrison DE, Strong R, Allison DB, Ames BN, Astle CM, Atamna H, Fernandez E, Flurkey K, Javors MA, Nadon NL, et al. 2014. Acarbose, 17-a-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell 13: 273-282.
44. Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L, et al. 2013. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diab Care 36: 1304-1311.
45. Howren MB, Lamkin DM, Suls J. 2009. Associations of depression with C-reactive protein, IL-1, and IL-6: A metaanalysis. Psychosom Med 71: 171-186.
46. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. 2004. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53: 693-700.
47. Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, Leu HB. 2011. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol 107: 1028-1033.
48. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, Green DM, Armstrong GT, Nottage KA, Jones KE, et al. 2013. Clinical ascertainment of health outcomes among adults treated for childhood cancer. J Am Med Assoc 309: 2371-2381.
49. Johnson JA, Simpson SH, Toth EL, Majumdar SR. 2005. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 22: 497-502.
50. Joost HG. 2014. Diabetes and cancer: Epidemiology and potential mechanisms. Diab Vasc Dis Res 11: 390-394.
51. Kanapuru B, Ershler WB. 2009. Inflammation, coagulation, and the pathway to frailty. Am J Med 122: 605-613.
52. Karnevi E, Said K, Andersson R, Rosendahl AH. 2013.Metformin- mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 13: 235.
53. Katsimpardi L, Litterman NK, Schein PA, Miller CM, Loffredo FS, Wojtkiewicz GR, Chen JW, Lee RT, Wagers AJ, Rubin LL. 2014. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 344: 630-634.
54. Kennedy BK, Pennypacker JK. 2014. Drugs that modulate aging: The promising yet difficult path ahead. Transl Res 163: 456-465.
55. Kirkland JL. 2013a. Translating advances from the basic biology of aging into clinical application. Exp Gerontol 48: 1-5.
56. Kirkland JL. 2013b. Inflammation and cellular senescence: Potential contribution to chronic diseases and disabilities with aging. Public Policy Aging Rep 23: 12-15.
57. Kirkland JL, Peterson C. 2009. Healthspan, translation, and new outcomes for animal studies of aging. J Gerontol A Biol Sci Med Sci 64: 209-212.
58. Kirkland JL, Tchkonia T. 2014. Clinical strategies and animal models for developing senolytic agents. Exp Gerontol 68: 19-25.
59. Lamanna C, Monami M, Marchionni N, Mannucci E. 2011. Effect of metformin on cardiovascular events and mortality: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 13: 221-228.
60. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, et al. 2012. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335: 1638-1643.
61. Lamming DW, Ye L, Sabatini DM, Baur JA. 2013. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 123: 980-989.
62. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. 2010.Metformin associatedwith lower cancer mortality in type 2 diabetes: ZODIAC-16. Diab Care 33: 322-326.
63. Lavasani M, Robinson AR, Lu A, Song M, Feduska JM, Ahani B, Tilstra JS, Feldman CH, Robbins PD, Niedernhofer LJ, et al. 2012. Muscle-derived stem/progenitor cell dysfunction limits healthspan and lifespan in a murine progeria model. Nat Commun 3: 608.
64. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. 2011. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer 11: 20.
65. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, Pistoia V, Wei M, Hwang S, Merlino A, et al. 2012. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 4: p124ra127.
66. Leng SX, Xue QL, Tian J, Walston JD, Fried LP. 2007. Inflammation and frailty in older women. J Am Geriatr Soc 55: 864-871.
67. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. 2010. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ 340: b5465.
68. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. 2009.Newusers of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diab Care 32: 1620-1625.
69. Linz W, Jessen T, Becker RH, Scholkens BA,Wiemer G. 1997. Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation 96: 3164-3172.
70. Linz W, Heitsch H, Scholkens BA, Wiemer G. 2000. Longterm angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats. Hypertension 35: 908-913.
71. Lipton RB, Hirsch J, Katz MJ, Wang C, Sanders AE, Verghese J, Barzilai N, Derby CA. 2010. Exceptional parental longevity associated with lower risk of Alzheimer’s disease and memory decline. J Am Geriatr Soc 58: 1043-1049.
72. Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. 2011. Potent anti-proliferative effects of metformin on trastuzumab- resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle 10: 2959-2966.
73. Lucicesare A, Hubbard RE, Searle SD, Rockwood K. 2010. An index of self-rated health deficits in relation to frailty and adverse outcomes in older adults. Aging Clin Exp Res 22: 255-260.
74. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A, Oddo S. 2012. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1b and enhancing NMDA signaling. Aging Cell 11: 326-335.
75. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, et al. 2014. mTOR inhibition improves immune function in the elderly. Sci Transl Med 6: 268ra179.
76. Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M, Grimm RH Jr, Howard BV, Assaf AR, Prentice R. 2005. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: The Women’s Health Initiative Observational Study. Arch Intern Med 165: 500-508.
77. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, Gomes AP, Ward TM, Minor RK, Blouin MJ, et al. 2013. Metformin improves healthspan and lifespan in mice. Nat Commun 4: 2192.
78. McLean RR, Shardell MD, Alley DE, Cawthon PM, Fragala MS, Harris TB, Kenny AM, Peters KW, Ferrucci L, Guralnik JM, et al. 2014. Criteria for clinically relevantweakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: The Foundation for the National Institutes of Health (FNIH) Sarcopenia Project. J Gerontol A Biol Sci Med Sci 69: 576-583.
79. Mercken EM, Mitchell SJ, Martin-Montalvo A, Minor RK, Almeida M, Gomes AP, Scheibye-Knudsen M, Palacios HH, Licata JJ, Zhang Y, et al. 2014. SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell 13: 787-796.
80. Minagawa S, Araya J, Numata T, Nojiri S, Hara H, Yumino Y, Kawaishi M, Odaka M, Morikawa T, Nishimura SL, et al. 2011. Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-b-induced senescence of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 300: L391-L401.
81. Mitchell SJ, Martin-Montalvo A, Mercken EM, Palacios HH, Ward TM, Abulwerdi G, Minor RK, Vlasuk GP, Ellis JL, Sinclair DA, et al. 2014. The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep 6: 836-843.
82. Monami M, Colombi C, Balzi D, Dicembrini I, Giannini S, Melani C, Vitale V, Romano D, Barchielli A, Marchionni N, et al. 2011.Metformin and cancer occurrence in insulin- treated type 2 diabetic patients. Diab Care 34: 129-131.
83. Moore BB, Hogaboam CM. 2008. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294: L152-160.
84. Ness KK, Armstrong GT, Kundu M, Wilson CL, Tchkonia T, Kirkland JL. 2014. Frailty in childhood cancer survivors. Cancer 121: 1540-1547.
85. O’Connor PM, Lapointe TK, Beck PL, Buret AG. 2010. Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis 16: 1411-1420.
86. Olshansky SJ, Carnes BA, Cassel C. 1990. In search of Methuselah: Estimating the upper limits to human longevity. Science 250: 634-640.
87. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, et al. 2004. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599-2610.
88. Pasternak B, Svanstrom H, Callreus T, Melbye M, Hviid A. 2011. Use of angiotensin receptor blockers and the risk of cancer. Circulation 123: 1729-1736.
89. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Amer Med Assoc 286: 327-334.
90. Qu T, Walston JD, Yang H, Fedarko NS, Xue QL, Beamer BA, Ferrucci L, Rose NR, Leng SX. 2009. Upregulated ex vivo expression of stress-responsive inflammatory pathway genes by LPS-challenged CD14þ monocytes in frail older adults. Mech Ageing Dev 130: 161-166.
91. Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, Hollander MC, Gills JJ, Dennis PA. 2013. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila) 6: 801-810.
92. Richardson A, Galvan V, Lin AL, Oddo S. 2014. How longevity research can lead to therapies for Alzheimer’s disease: The rapamycin story. Exp Gerontol 68: 51-58.
93. Rockwood K, Mitnitski A. 2011. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clin Geriatr Med 27: 17-26.
94. Rockwood K, Mitnitski A, Song X, Steen B, Skoog I. 2006. Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc 54: 975-979.
95. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR. 2012. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study. Ann Intern Med 157: 601-610.
96. Ryu JH, Moua T, Daniels CE, Hartman TE, Yi ES, Utz JP, Limper AH. 2014. Idiopathic pulmonary fibrosis: Evolving concepts. Mayo Clin Proc 89: 1130-1142.
97. Salani B, Maffioli S, Hamoudane M, Parodi A, Ravera S, Passalacqua M, Alama A, Nhiri M, Cordera R, Maggi D. 2012. Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. FASEB J 26: 788-798.
98. Santos EL, de Picoli Souza K, da Silva ED, Batista EC, Martins PJ, D’Almeida V, Pesquero JB. 2009. Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochem Pharmacol 78: 951-958.
99. Schetter AJ, Heegaard NH, Harris CC. 2010. Inflammation and cancer: Interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31: 37-49.
100. Seibel SA, Chou KH, Capp E, Spritzer PM, von Eye Corleta H. 2008. Effect of metformin on IGF-1 and IGFBP-1 levels in obese patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 138: 122-124.
101. Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, et al. 2011. Accelerating drug discovery for Alzheimer’s disease: Best practices for preclinical animal studies. Alzheimers Res Ther 3: 28.
102. Sinha M, Jang YC, Oh J, Khong D, Wu EY, Manohar R, Miller C, Regalado SG, Loffredo FS, Pancoast JR, et al. 2014. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 344: 649-652.
103. Smith DL Jr, Elam CF Jr, Mattison JA, Lane MA, Roth GS, Ingram DK, Allison DB. 2010. Metformin supplementation and life span in Fischer-344 rats. J Gerontol A Biol Sci Med Sci 65: 468-474.
104. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. 2003. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52: 812-817.
105. Srikrishna G, Freeze HH. 2009. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 11: 615-628.
106. Steinmetz KL, Spack EG. 2009. The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurol 9: pS2.
107. Strong R, Miller RA, Astle CM, Floyd RA, Flurkey K, Hensley KL, Javors MA, Leeuwenburgh C, Nelson JF, Ongini E. 2008.Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell 7: 641-650.
108. Takasaka N, Araya J, Hara H, Ito S, Kobayashi K, Kurita Y, Wakui H, Yoshii Y, Yumino Y, Fujii S, et al. 2014. Autophagy induction by SIRT6 through attenuation of insulinlike growth factor signaling is involved in the regulation of human bronchial epithelial cell senescence. J Immunol 192: 958-968.
109. Tatar M. 2009. Can we develop genetically tractable models to assess healthspan (rather than life span) in animal models? J Gerontol A Biol Sci Med Sci 64: 161-163.
110. Tchkonia T, Morbeck DE, von Zglinicki T, van Deursen J, Lustgarten J, Scrable H, Khosla S, Jensen MD, Kirkland JL. 2010. Fat tissue, aging, and cellular senescence. Aging Cell 9: 667-684.
111. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. 2013. Cellular senescence and the senescent secretoryphenotype: Therapeutic opportunities. J Clin Invest 123: 966-972.
112. Tosca L, Rame C, Chabrolle C, Tesseraud S, Dupont J. 2010. Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells. Reproduction 139: 409-418.
113. Tseng CH. 2012. Diabetes, metformin use, and colon cancer: A population-based cohort study in Taiwan. Eur J Endocrinol 167: 409-416.
114. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. 2006. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population- based, prospective study. Thromb Haemost 95: 511-518.
115. Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, Napoli N, Qualls C, Shah K. 2011.Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 364: 1218-1229.
116. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, Gottdiener J, Fried LP. 2002. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: Results from the Cardiovascular Health Study. Arch Intern Med 162: 2333-2341.
117. Walston J, Hadley E, Ferrucci L, Guralnick JM, Newman AB, Studenski SA, Ershler WB, Harris T, Fried LP. 2006. Research agenda for frailty in older adults: Toward a better understanding of physiology and etiology: Summary from the American Geriatrics Society/ National Institute on Aging research conference on frailty in older adults. J Am Geriatr Soc 54: 991-1001.
118. Walston JD, Matteini AM, Nievergelt C, Lange LA, Fallin DM, Barzilai N, Ziv E, Pawlikowska L, Kwok P, Cummings SR, et al. 2009. Inflammation and stress-related candidate genes, plasma interleukin-6 levels, and longevity in older adults. Exp Gerontol 44: 350-355.
119. Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM. 2013. Chronic metformin associated cardioprotection against infarction: Not just a glucose lowering phenomenon. Cardiovasc Drugs Ther 27: 5-16.
120. Zeymer U, Schwarzmaier-D’assie A, Petzinna D, Chiasson JL. 2004. Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: Results of the randomised STOP-NIDDM trial electrocardiography substudy. Eur J Cardiovasc Prev Rehabil 11: 412-415.